MDS Nordion signs agreement to manufacture Molecular Insight's BMIPP
MDS Nordion, a part of MDS Inc., and Molecular Insight Pharmaceuticals Inc. of Cambridge, Mass., last week inked a development and contract manufacturing agreement to produce BMIPP. BMIPP is Molecular's lead molecular imaging pharmaceutical.
According to MDS, BMIPP is currently in a multi-center PhaseIIb clinical trial in the United States for the detection of cardiac ischemia in the emergency department setting. The compound has the ability to detect ischemia in chest pain patients at rest up to 30 hours after a cardiac event occurs.
BMIPP is labeled with MDS's high-purity iodine-123 to provide superior imaging quality. The new cardiac imaging pharmaceutical will be manufactured at MDS's cyclotron facility in Vancouver, Canada.
According to MDS, BMIPP is currently in a multi-center PhaseIIb clinical trial in the United States for the detection of cardiac ischemia in the emergency department setting. The compound has the ability to detect ischemia in chest pain patients at rest up to 30 hours after a cardiac event occurs.
BMIPP is labeled with MDS's high-purity iodine-123 to provide superior imaging quality. The new cardiac imaging pharmaceutical will be manufactured at MDS's cyclotron facility in Vancouver, Canada.